Refractory Hematologic Malignancy Clinical Trials in Barcelona
2 recruitingBarcelona, Spain
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
International Leukemia Target Board
Relapsed Hematologic MalignancyRefractory Hematologic Malignancy
Princess Maxima Center for Pediatric Oncology600 enrolled7 locationsNCT05270096